Medline Inc. (MDLN)
Medline Inc. manufactures med-surg products serving the hospital, surgery centers, physician offices, post-acute facilities, and nursing home sites of care in the United States and Internationally. It operates through two segments: Medline Brand and Supply Chain Solutions. The Medline Brand segment procures and manufactures products from three product categories include surgical solutions, front line care, and laboratory and diagnostics. Its front line care offers med-surg products for patient-facing needs, including wound care products, exam gloves, skin care and incontinence products, environment cleaning supplies, textiles, hand sanitizer, durable medical equipment, patient plastics, and decolonization and infection control products. Its surgical solutions provide operating room and perioperative environment product solutions, including surgical procedure trays, drapes and gowns, personal protective equipment, sterile wraps, surgical instruments, surgeon's gloves, procedure kits, and orthopedic implants. Its laboratory and diagnostics offer laboratory and diagnostic product solutions, including point of care testing, analyzers and instrumentation, lab and diagnostic consumables, diagnostic instruments, vital signs monitors, and anatomic pathology and phlebotomy products. It provides its products to domestic and international consumers. The Supply Chain Solutions segment procures and distributes a variety of third-party products from national brands. It provides logistics and supply chain optimization services to domestic and international consumers. It also provides supply chain optimization services, such as consulting engagements, outsourced warehouse and technology management, put-away-ready packaging, third-party logistics, inventory rationalization, and route planning. The company was founded in 1966 and is based in Northfield, Illinois.
- Symbol
- MDLN
- Exchange
- Nasdaq
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies
- Market cap
- $29.37B
- 52 week range
- 31.49 - 50.88
Valuation
- Share price
- $34.30 (close of 2026-09-23)
- P/E (TTM)
- 33.28x
- Price to book
- 1.54x
- Price to free cash flow
- 18.46x
- Enterprise value
- $39.33B
- Book value per share
- $22.27
Price performance
| Period | Change |
|---|
| 1 day | +7.32% |
| 5 days | +6.82% |
| 1 month | +0.12% |
| 3 months | -2.83% |
| 6 months | -19.26% |
| Year to date | -18.33% |
| All time | -16.34% |
Profitability and growth
- Return on equity
- 6.01%
- Return on invested capital
- 7.08%
- Return on assets
- 3.01%
- Return on capital employed
- 6.15%
- Gross margin
- 26.44%
- Net margin
- 4.08%
- EBITDA margin
- 11.34%
- Net income growth
- 0.52%
- Free cash flow growth
- 0.00%
Cash flow and balance sheet
- Free cash flow yield (TTM)
- 5.42%
- Current ratio
- 4.33x
- Net debt to EBITDA
- 3.26x
Latest reported year
- Period end
- 2025-12-31
- Fiscal year
- 2025
- Revenue
- $28.43B
- Cost of revenue
- $20.91B
- Gross profit
- $7.52B
- EBITDA
- $3.22B
- Net income
- $1.16B
- Earnings per share
- $-0.01
- Research and development
- $80.00M
- Shares outstanding
- 810.00M
Income statement by year
| Period end | Revenue | Gross profit | Net income | EPS |
|---|
| 2025-12-31 | $28.43B | $7.52B | $1.16B | $-0.01 |
| 2025-12-16 | - | - | $1.15B | $1.42 |
| 2024-12-31 | $25.51B | $6.98B | $1.16B | $0.64 |
| 2023-12-31 | $23.23B | $5.88B | $234.00M | $0.13 |
Margins and returns by year
| Period end | Gross margin | Net margin | Return on equity | Return on capital |
|---|
| 2025-12-31 | 26.44% | 4.08% | 6.01% | 7.08% |
| 2025-12-16 | - | - | 0.00% | - |
| 2024-12-31 | 27.35% | 4.56% | 7.04% | 6.32% |
| 2023-12-31 | 25.33% | 1.01% | 0.00% | - |
Cash and debt by year
| Period end | Cash | Debt |
|---|
| 2025-12-31 | $1.94B | $12.48B |
| 2024-12-31 | $199.00M | $16.42B |
Free cash flow by year
| Period end | Free cash flow | Stock-based compensation |
|---|
| 2025-12-31 | $1.30B | $76.00M |
| 2024-12-31 | $1.42B | $61.00M |
| 2023-12-31 | $1.41B | $78.00M |
Investor relations
Next earnings report
- Next confirmed report
- 2026-11-04
- Consensus EPS estimate
- $0.32
Past earnings dates
| Reported | Fiscal period | EPS estimate |
|---|
| 2026-08-05 | Jun/2026 | $0.30 |
| 2026-05-06 | - | - |
| 2026-02-25 | - | - |
Filings and sources
- Company website
- medline.com
- SEC filings
- 10-K, 10-Q and 8-K on EDGAR
- Earnings calendar
- All upcoming reports
Similar companies
Intuitive Surgical Inc (ISRG) · Becton Dickinson & Co (BDX) · ResMed Inc (RMD) · West Pharmaceutical Services Inc (WST) · Baxter International Inc (BAX) · Align Technology Inc (ALGN) · Cooper Companies, Inc. (COO) · Vertex Pharmaceuticals Inc (VRTX)
All Healthcare companies
Understanding these figures
Price-to-earnings ratio · Discounted cash flow · Free cash flow · Earnings per share · Return on equity · Gross margin vs net margin · Reading a balance sheet · Debt and leverage · Dividend yield · Insider transactions and Form 4 · How to read a stock chart
Explore
Company directory · S&P 500 heatmap · Earnings calendar · Super investor holdings · Congress trades